Phase III WAYPOINT trial found that Tezspire (tezepelumab-ekko) effectively reduced nasal polyp size and congestion in patients with chronic rhinosinusitis with nasal polyps, offering a promising new treatment option with a consistent safety profile.
In the first part of this roundtable discussion, a panel of experts introduce themselves and highlight the challenges industry is seeing with underrepresentation of racial and ethnic groups in clinical trials.
Two-part study will evaluate the safety and tolerability of ZW191 in solid tumors across a variety of cancers including ovarian and endometrial.
An interim analysis of the Phase III ALIGN trial found that 36 weeks of treatment with atrasentan significantly reduced proteinuria in high-risk IgA nephropathy patients with a favorable safety profile, supporting its potential role in managing the disease.
In this video interview, Jay Park, founder & scientific lead, Core Clinical Sciences, discusses how risk-based monitoring can alert sponsors of falling short of enrollment goals.
Trial data over 30 days showed the novel Intravascular Lithotripsy catheter safely modified calcium, enabling effective treatment.
The STEP 9 trial found that once-weekly semaglutide significantly reduced knee osteoarthritis pain and body weight in patients with obesity, improved physical function, and potentially reduced the need for NSAIDs and opioids.
In this video interview, Rebecca Metcalfe, principal scientist, patient-centered research, Core Clinical Sciences, highlights the consequences of focusing solely on enrollment targets.
An overview of key trends in communication, logistical preferences, and demographic influences that shape patient engagement and retention in clinical trials.
In this video interview, Jay Park, founder & scientific lead; and Rebecca Metcalfe, principal scientist, patient-centered research; both with Core Clinical Sciences, share their reactions to the FDA releasing its Diversity Action Plan Guidance.
Results showed significantly improved social functioning and quality of life across three different doses.
In this video interview, Jay Park, founder & scientific lead; and Rebecca Metcalfe, principal scientist, patient-centered research; both with Core Clinical Sciences, discuss a recent article they authored on the guidance.
A post hoc analysis of the SELECT trial shows semaglutide 2.4 mg significantly reduced hospital admissions and hospital stay lengths in adults with obesity or overweight and cardiovascular disease but without diabetes.
New partnership leverages Google’s infrastructure and artificial intelligence capabilities.
Cobenfy (xanomeline and trospium chloride) demonstrated sustained long-term efficacy, safety, and tolerability over 52 weeks in Phase III trials for adult schizophrenia patients, showing significant symptom improvement and quality of life benefits with minimal adverse effects.
In this video interview, Jimmy Bechtel, vice president, site engagement, SCRS, provides an overview of themes discussed and his key takeaways from the most recent summit.
Our October issue focused on the current state of outsourcing with additional coverage around site networks and risk-based quality management.
INAVO120 Phase III trial shows Itovebi (inavolisib) plus Ibrance (palbociclib) and Faslodex (fulvestrant) is a promising first-line treatment option that effectively targets disease pathways with durable clinical benefits for PIK3CA-mutated, endocrine-resistant, HR-positive, HER2-negative metastatic breast cancer.
In this video interview, Jimmy Bechtel, vice president, site engagement, SCRS, discusses some key initiatives around decentralized capabilities and underrepresented patient populations.
Results across two studies showed patients sustained stable, long-term remission.
EMPA-KIDNEY trial shows that two years of treatment with Jardiance (empagliflozin) significantly lowered the risk of chronic kidney disease progression and cardiovascular death, with lasting cardiorenal benefits up to one year after treatment ended.
In this video interview, Jimmy Bechtel, vice president, site engagement, SCRS, highlights ongoing leadership and payment initiatives for sites.
The INTerpath-009 clinical trial will evaluate the combination as adjuvant treatment for patients with NSCLC who previously received neoadjuvant Keytruda plus platinum-based chemotherapy.
Phase III GRAVITI trial results show Tremfya (guselkumab) administered subcutaneously provides significant clinical remission and endoscopic response at 48 weeks for patients with moderate to severe Crohn's disease, offering a promising new treatment option with both subcutaneous and intravenous induction routes.
In this video interview, Jimmy Bechtel, vice president, site engagement, SCRS, discusses the importance of communication between CROs, sponsors, and sites.
Omvoh (mirikizumab) becomes the first IL23p19 antagonist to show multi-year, long-term sustained efficacy in both ulcerative colitis and Crohn disease, with Phase III trials showing high rates of clinical and endoscopic remission with a consistent safety profile.
In this video interview, Jimmy Bechtel, vice president, site engagement, SCRS, highlights how sites are bearing the burdens of cost and training with implementing new technologies.
A number of topics including DE&I, collaboration, and decentralized trials have been front and center at the clinical research industry’s largest meetings.
Ebglyss (lebrikizumab-lbkz) shows significant efficacy in reducing skin symptoms and itch in moderate-to-severe atopic dermatitis patients, including those who previously discontinued Dupixent.
In this video interview, Jimmy Bechtel, vice president, site engagement, SCRS, discusses challenges and trends he is currently hearing about from sites.
